Denosumab for the Management of Hypercalcemia of Malignancy in Patients With Multiple Myeloma and Renal Dysfunction

Cicci, Jonathan D.; Buie, Larry W.; Bates, Jill; Deventer, Hank van

doi:10.1016/j.clml.2014.07.005

Cited by 44 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given its mechanism of action, it has been successfully used to treat bisphosphonate-refractory, malignant hypercalcemia due to MM [48,49]. This could be a valuable therapeutic agent in the future for the management of myelomarelated hypercalcemia given the upregulation of the RANKL pathway in this disease.…”

Section: Do Tackle Hypercalcemia Aggressivelymentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

In the era of novel biological agents, multiple myeloma (MM) is often approached as a chronic condition. While survival continues to improve, population‐level data indicate that early mortality remains a substantial barrier to advances in MM outcomes. Here we provide “do's and don'ts” management recommendations that may minimize the risk of early mortality and ensure that patients have the opportunity to benefit from the long term impact of new effective MM agents. Such recommendations encompass the early introduction of novel agents even in the presence of comorbidities and advanced age and aggressive management of MM‐related complications. Am. J. Hematol. 91:101–108, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Do Tackle Hypercalcemia Aggressivelymentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…There had been similar cases with pseudohypercalcemia in patients with multiple myeloma (5-7). As Cicci et al described (8), hypercalcemia can complicate the management of myeloma by precipitating dehydration and prerenal azotemia as our patient had azotemia. It has been also reported that a standard approach to hypercalcemia following a malignancy is fluid resuscitation (9).…”

Section: A R T I C L E I N F Omentioning

confidence: 57%

Pseudohypercalcemia in a patient with multiple myeloma and acute kidney injury; a case report

Khaledi¹,

Salehidoost²,

Khosravifarsani³

et al. 2019

J Nephropharmacol

View full text Add to dashboard Cite

“…10,19 In our study, at least VGPR rate was 46.88% in patients received bortezomib-based therapy, and 23.08% for those treated with thalidomide-based com- 20,21 It is essential to be able to recognize the symptoms of myeloma in clinical routine and to be aware of basic diagnostic features to confirm this disease and give timely treatment. [21][22][23][24] In addition, β 2 -microglobulin (β 2 M) is expressed on the surface of all nucleated cell and associated with the major histocompatibility complex I (MHC-I)/human leukocyte antigen I (HLA-I) to facilitate antigen presentation. 25 β 2 M, which has been introduced into staging system of MM and thought to a reflection of renal function and the tumor cell burden, has been regarded as the most important prognostic factor in MM.…”

Section: Discussionmentioning

confidence: 99%

Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis

Song

Jiang

Liu

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Renal failure is a severe complication of symptomatic myeloma, related to higher mortality. Recovery from dialysis dependence can lead to enormous survival benefits. We investigated the effect factors for probability of dialysis independence. Methods Retrospective data on 45 newly diagnosed MM (NDMM) patients with serious renal impairment and requiring hemodialysis were analyzed. The statistical methods including logistic regression analysis, Kaplan‐Meier survival curves, the log‐rank test and the Cox proportional hazards model for survival analysis were used in our study. Results Twenty‐two of the 45 patients, who were on hemodialysis at diagnosis, became dialysis independence. In the logistic regression analysis, serum level of β2‐microglobulin, kidney disease history, involved free light chain, and achieving at least VGPR were significantly associated with reversibility from dialysis dependence. In addition, achieving hemodialysis discontinuation was related to better survival. The multivariate analyses demonstrated that reversibility from dialysis dependence, proteinuria < 3.5 g/24 h, and achieving at least VGPR were significantly associated with OS among NDMM patients requiring hemodialysis. Conclusion Lower serum level of β2‐microglobulin and lower level of free light chain at diagnosis, achieving at least VGPR, and shorter kidney disease history are related to a high probability of dialysis independence in NDMM patients with serious renal failure requiring dialysis.

show abstract

Denosumab for the Management of Hypercalcemia of Malignancy in Patients With Multiple Myeloma and Renal Dysfunction

Cited by 44 publications

References 16 publications

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

Pseudohypercalcemia in a patient with multiple myeloma and acute kidney injury; a case report

Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis

Contact Info

Product

Resources

About